Ottawa researchers have unlocked a way to make pancreatic cancer cells more vulnerable to cancer-killing viruses, known as oncolytic viruses. Outlined in a paper published recently, the scientists have discovered how they can exploit the communication, or cross-talk, between pancreatic cancer and a specific cell type that supports the tumor. They found that this cross-talk weakens the ability of both cell types to fight off cancer-fighting viruses.
The cross-talking cells in question are called cancer-associated fibroblasts (or CAFs), which are genetically normal cells that the cancer has conditioned to support the tumor. This conditioning by the tumor makes the CAFs susceptible to virus infection, compared to their normal counterparts. In turn, the CAFs secrete a protein called FGF2 that makes the tumors more susceptible to virus infection.
Pancreatic cancer is among the deadliest of cancers, killing approximately 4,400 Canadians every year. Only 6 per cent of people diagnosed with pancreatic cancer live longer than 5 years — a survival rate that has not improved in the last 40 years.
CAFs make tumours more resistant to standard therapies and pancreatic cancers are known to have a lot of CAFs. This study shows that the opposite is true when it comes to cancer fighting viruses. More CAFs and higher levels of FGF2 make them more susceptible to oncolytic virus therapy.
"Our findings could be important for patients in a couple of ways," said Dr. John Bell (pictured), the study’s author and a senior scientist at the Ottawa Hospital Research Institute and professor of medicine at the University of Ottawa. "First, they could help us predict which cancer patients will be more likely to respond to oncolytic virus treatment.”
"More importantly, we saw improved outcomes in tumors treated with an oncolytic virus that expressed FGF2," added Dr. Bell, who is also scientific director of BioCanRX, a new network devoted to accelerating the journey of promising cancer biotherapeutic discoveries from the lab to clinical trials. "Combined with the fact that the 5-year survival rate for pancreatic cancer has been stuck in the single digits, we are motivated to move this knowledge into clinical testing."
The experiments for this paper, whose lead author is postdoctoral fellow Dr. Carolina Ilkow, were conducted with mouse models and cells from human patients with pancreatic cancer. The findings require further study before they can be translated into a clinical trial.
Still, the paper is positive news for at least one woman living with pancreatic cancer.
"This discovery is so encouraging to me, even though I fully realize it's still at an early stage," said Sindy Hooper, an Ottawa mother of two and triathlete who was diagnosed with pancreatic cancer in January 2013. "For me, research progress like this means hope, and that hope helps me live with the stark reality of my diagnosis."
Hooper recently passed her latest 6-month cancer screening, but she says that if her cancer comes back, she will think long and hard about whether or not to undergo chemotherapy again, because the side effects were so bad.
One of the potential benefits of oncolytic virus therapy is that it is far less toxic than standard chemotherapy. Oncolytic viruses attack and kill cancer cells while leaving healthy cells unharmed. The expected side effects of oncolytic virus treatments being tested in clinical trials are usually a mild fever or flu-like symptoms that last a day or two.
Illustration: Ottawa Hospital Research Institute.
Ottawa Hospital Research Institute News Release (04/20/15)
Science Daily (04/20/15)
Abstract (Nature Medicine; 21, 530-536 (04/20/15))